314765-83-8

Basic information

• Product Name: N-(4-chloro-3-nitrophenyl)-N'-(4-fluorophenyl)thiourea
• Synonyms: 1-(4-chloro-3-nitrophenyl)-3-(4-fluorophenyl)thiourea;N-(4-chloro-3-nitrophenyl)-N'-(4-fluorophenyl)thiourea;Thiourea, N-(4-chloro-3-nitrophenyl)-N'-(4-fluorophenyl)-
• CAS NO: 314765-83-8
• Molecular Formula: C13H9ClFN3O2S
• Molecular Weight: 325.75
• Mol File: 314765-83-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4-chloro-3-nitrophenyl)-N'-(4-fluorophenyl)thiourea(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-chloro-3-nitrophenyl)-N'-(4-fluorophenyl)thiourea(314765-83-8)
• EPA Substance Registry System: N-(4-chloro-3-nitrophenyl)-N'-(4-fluorophenyl)thiourea(314765-83-8)

Safety Data

• Hazardous Substances Data: 314765-83-8(Hazardous Substances Data)

Upstream product

• 635-22-3 4-Chloro-3-nitroaniline 
• 1544-68-9 4-fluorophenyl isothiocyanate 
• 371-40-4 4-fluoroaniline 
• 1195-45-5 para-fluorophenyl isocyanate 

Relevant articles and documents

Synthesis and Antimicrobial Activity of 4-Chloro-3-Nitrophenylthiourea Derivatives Targeting Bacterial Type II Topoisomerases

A series of novel 4-chloro-3-nitrophenylthiourea derivatives were synthesized and evaluated for their antimicrobial, antibiofilm and tuberculostatic activities. Most of compounds exhibited high antibacterial activity against both standard and hospital strains (MIC values 0.5-2 μg/mL), as compared to Ciprofloxacin. Derivatives with 3,4-dichlorophenyl (11) and 3-chloro-4-methylphenyl (13) substituents were the most promising towards Gram-positive pathogens. Both of them exhibited antibiofilm potency and effectively inhibited the formation of biofilms of methicillin-resistant and standard strains of Staphylococcus epidermidis. Two N-alkylthioureas (20, 21) showed twofold to fourfold increase in in vitro potency against isolates of Mycobacterium tuberculosis, as compared to Isoniazid. An action of 7, 10, 11, 13, 20 and 21 against activity of topoisomerases isolated from Staphylococcus aureus was studied. Synthesized compounds were found as non-genotoxic.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.